Achillion Pharmaceuticals, Inc.

Akihiro Hashimoto

Avinash S Phadke

Jason Allan Wiles

Milind Deshpande

Qiuping Wang

Godwin Pais

Venkat Rao Gadhachanda

Xiangzhu Wang

Dawei Chen

Atul Agarwal

William J Greenlee

Kyle J Eastman

Joel Charles Barrish

Barton James Bradbury

Edlaine Lucien

Ha Young Kim

Michael Pucci

Cuixian Liu

Mark Andres

Suoming Zhang

Pingyun Chen

Shouming Li

Godwin Clarence Gilroy Pais

Wei Ma

Senthil Kumar Kusalakumari Sukumar

Yongsheng Song

Lee M Katrincic

Quiping Wang

Michael John Pucci

Godwin Clarence Pais

Atul Ararwal

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I″ and I'″ or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein Ror Ron the A group is an aryl, heteroaryl or heterocycle (R) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Pharmaceutical compounds for treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I″ and I′″ or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

This invention provides stable, highly crystalline forms of Complement factor D inhibitors Compound 1 for advantageous therapeutic pharmaceutical efficacy and dosage form stability.

Morphic forms of danicopan

This invention provides stable, highly crystalline forms of Complement Factor D inhibitor Compound 3 for therapeutic applications.

Morphic forms of complement factor D inhibitors

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I&#x2033; and I'&#x2033; or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Amide compounds for treatment of immune and inflammatory disorders

Amino compounds for treatment of immune and inflammatory disorders

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, or a pharmaceutically acceptable salt or composition thereof. The inhibitors of Factor D described herein reduce the excessive activation of complement, and are useful to treat disorders mediated by the complement system.

Disubstituted compounds for treatment of medical disorders

Growing community of inventors

Branford, CT, United States of America

Akihiro Hashimoto